Prior to the exhibition, the professional team looked forward to extolling the advantages of PerioChip®. EuroPerio 8 was a fantastic place for PerioChip® to raise awareness amongst the dental community about gum disease and its potential links to systemic illnesses such as diabetes and cardiovascular disease.
The speakers taking to the stage at the show included: Professor Eli Machtei, Professor Arie J Van Winkelhoff and Dr Rajan Nansi.
Professor Machtei of the Rambam School of Dentistry in Israel is Clinical Associate Professor at the Faculty of Medicine at the Technion (Israel Institute of Technology in Haifa, Israel). His session, Guided Tissue Regeneration: When to use it, focused on periodontal regeneration and looked at how far the profession has progressed and what future research is needed in order to improve our clinical outcomes. He asked what the limitations are, and where should dentists complete or refrain from completing guided tissue regeneration.
Professor Arie J Van Winklehoff of the University of Groningen in the Netherlands is Co-owner of Laboral Diagnostics en Laboral International, a service in the field of clinical microbiology for dental professionals. His session, When should we use systemic antimicrobials? discussed the rationale behind using these drugs in treating periodontitis. It considered the recent World Health Organisation recommendations surrounding the over-prescription of antimicrobial medicines and encouraged a more evidence-based approach to the prescription of antibiotics for periodontitis.
Dr Rajan Nansi, Chair of Early Careers Group, BSP UK also spoke at the event and his session, Management of periodontitis in practice: Practical concepts, aimed to discuss the effectiveness of non-surgical periodontal therapy and explore the use of adjunctive locally applied antimicrobials in periodontal treatment.
Delegates at EuroPerio 8 could see that PerioChip® is passionate about supporting, educating and communicating with the dental community to highlight the importance of keeping gums healthy, and treating gum disease effectively without the risk associated with using antibiotics.
This is where the advantages of this wafer thin biodegradable insert really come into their own. By using PerioChip® you can ensure that harmful bacteria are eliminated for up to 10 days[i] and, for on-going therapy, PerioChip® suppresses the growth of bacterial flora in the treated site for up to 11 weeks, giving the all-important time needed for gum reattachment and stabilisation of the periodontium[ii].
Summary of product link;
Abbreviated Prescribing Information
PerioChip® 2.5mg Dental Insert (Chlorhexidine digluconate)
For full prescribing information, including side effects, precautions and contraindications, see Summary of Product Characteristics (SmPC).
Presentation: Dental insert: bullet shaped orange brown containing Chlorhexidine digluconate 2.5mg.
Indications: PerioChip® is an adjunctive antimicrobial treatment for moderate to severe chronic periodontal disease in adults with pocketing, combined with Root Surface Debridement (RSD). Not indicated in children and adolescents.
Dosage and Administration: One PerioChip® is inserted into a periodontal pocket with a probing pocket depth of ?5mm. Retreatment with PerioChip® following mechanical plaque removal at 3 month intervals may provide additional benefit if pocket depth remains ?5mm. For details see SmPC. Removal is unnecessary as PerioChip® biodegrades.
Contraindications: Hypersensitivity to Chlorhexidine digluconate or excipients.
Precautions: Allergic reactions have occurred but are rare.
Interactions: Avoid nystatin: antagonistic of Chlorhexidine. Chlorhexidine is incompatible with anionic agents present in some toothpastes and with dietary sucrose, but there is no significant impact on the efficacy of PerioChip®.
Undesirable effects: During the first few days after insertion, transient pain or discomfort of gums or teeth; redness and/or swelling of the gums.
Overdose: Not reported
Pregnancy/ Lactation: Controlled studies in pregnant women have not been conducted, so weigh expected benefits against possible foetal risks: caution in nursing mothers (see SmPC).
NHS list price: £207.20
Legal category: P, Product Licence Number: PL 14017/0035
MA holder: Full prescribing information is available on request from Dexcel Pharma Ltd, 7 Sopwith Way, Drayton Fields Industrial Estate, Daventry, Northants, NN11 8PB.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to:
Dexcel Pharma Ltd on 01748 828784
[i] Jeffcoat M K et al. Adjunctive use of a subgingival controlled-release chlorhexidine chip. J Periodontal 1998; 69 (9): 989 – 997. http://www.ncbi.nlm.nih.gov/pubmed/9776027 [Accessed 26th May 2015]
[ii] Summary of Characteristics PerioChip® http://www.old.health.gov.il/units/pharmacy/trufot/alonim/PerioChip_dr_1337488974840.pdf [Accessed 26 May 2015]